Review
Drug evaluation: Bay-59-8862
Affiliations
- PMID: 15197663
Item in Clipboard
Review
Drug evaluation: Bay-59-8862
IDrugs.
2004 Jun.
Abstract
Bayer Corp, under license from Indena SpA, is developing BAY-59-8862, a taxane synthesized from 14beta-hydroxy-10-deacetylbaccatin III, for the potential treatment of cancer.
Similar articles
-
Taxane effect in a bladder washing.Diagn Cytopathol. 2015 Jan;43(1):32-3. doi: 10.1002/dc.23046. Epub 2014 Mar 19. Diagn Cytopathol. 2015. PMID: 24644138 No abstract available.
-
Synthesis and biological evaluation of methoxylated analogs of the newer generation taxoids IDN5109 and IDN5390.Bioorg Med Chem Lett. 2005 Dec 1;15(23):5182-6. doi: 10.1016/j.bmcl.2005.08.066. Epub 2005 Sep 23. Bioorg Med Chem Lett. 2005. PMID: 16183281
-
GM1 for taxane-induced neuropathy in breast cancer.Lancet Oncol. 2019 Jul;20(7):e348. doi: 10.1016/S1470-2045(19)30373-0. Epub 2019 May 23. Lancet Oncol. 2019. PMID: 31130320 No abstract available.
-
Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature.Ann Oncol. 2012 Dec;23(12):3016-3023. doi: 10.1093/annonc/mds170. Epub 2012 Aug 8. Ann Oncol. 2012. PMID: 22875836 Review.
-
Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.Cancer Chemother Pharmacol. 2015 Oct;76(4):679-90. doi: 10.1007/s00280-015-2818-4. Epub 2015 Jul 22. Cancer Chemother Pharmacol. 2015. PMID: 26198313 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical